sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models

This publication has 16 references indexed in Scilit:

• Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2
  The Lancet Infectious Diseases, 2024
• Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
  The Lancet Infectious Diseases, 2023
• CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential
  Experimental & Molecular Medicine, 2023
• Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
  Journal of Medical Virology, 2022
• A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models
  Molecular Therapy, 2022
• Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
  ACS Central Science, 2021
• Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance
  Cell, 2019
• Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses
  Molecular Therapy, 2018
• T cell exhaustion
  Nature Immunology, 2011
• Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
  Immunity, 2005